聊城看癫痫多少钱菏泽看羊癫疯病的医院在哪里,河北哪家医院看癫痫病好啊襄阳可以治吗,滨州治疗癫痫病最正规的医院,河南都有哪些癫痫医院,济南治疗医院羊癫疯专病那家好,江苏治疗癫痫的好方案,山东比较好的羊癫疯病医院

SAN FRANCISCO, Oct. 13 (Xinhua) -- The Internet search giant Google on Thursday released its third fiscal quarter earnings report, posting strong numbers that beat analysts' estimates.The Mountain View, California-based company reported revenue of 9.72 billion U.S. dollars for the quarter ending Sept. 30, 2011, an increase of 33 percent on a year-on-year basis.Google reported a profit of 2.73 billion dollars, compared to 2. 17 billion dollars in the same period last year. The earning per share, excluding certain items, is 9.72 dollars, topping the average estimate of 8.74 dollars per share polled by Thomson Reuters."We had a great quarter," said Google co-founder and Chief Executive Officer Larry Page in a statement. "Google+ is now open to everyone and we just passed the 40 million user mark. People are flocking into Google+ at an incredible rate and we are just getting started."Many analysts took the third quarter to examine the company's progress towards expanding its core business beyond advertising which accounted for 96 percent of its revenue last year. In the past quarter, Google made major investments in several key businesses, such as social networking and mobile.In August, Google announced a 12.5-billion-dollar acquisition of Motorola Mobility, a move widely seen to get Motorola's patent portfolio to protect its Android software against a growing number of infringement lawsuits by rival mobile platforms. The deal is expected to close later this year or early next year.Since its late-June launch, the Google+ social network has been receiving a good response, posing to shake up the social networking space dominated by Facebook.In September, Google also officially launched Google Wallet, a mobile payment allowing users to pay by tapping an Android smartphone against a compatible card reader.

BEIJING, Nov. 24 (Xinhua) -- In response to public suspicion stoked by recent dumpling contamination scandals, China's Ministry of Health on Thursday said the new food safety standard for flash-frozen dumplings did not show signs of leniency.The Ministry introduced the new food safety standard on flash-frozen dough or rice products on Thursday.The Ministry has been accused of loosening scrutiny over a disease-generating bacteria in such foods, staphylococcus aureus, or golden staph, which can cause various diseases, including pneumonia and sepsis, and is sometimes life-threatening.The controversy became particularly relevant after several major brands of frozen dumplings have been successively recalled in recent months.In October, a Henan-based company, Zhengzhou Sinian Food Co., Ltd, confirmed the contamination of golden staph in its flash-frozen seafood- and pork-stuffed dumplings.Frozen dumplings made by Hong Kong-based manufacturer Wanchai Ferry were found to contain golden staph in November, and some of its products have been pulled from shelves.The previous standard provided that no golden staph should be tested in such food, while the new one gives a quantitative restriction that the volume of the bacteria should be no more than ten to the fourth degree.Liu Xiumei, a food safety expert with the Chinese Center for Disease Control and Prevention, said at the press conference held by the health ministry that such bacteria becomes inactivate after the food is boiled for a few seconds, and it takes a volume of ten to the fifth degree to generate toxicity.The previous standard could only serve as a general provision due to the lack of quantitative microbiological testing back when it was introduced, Liu said, stressing that the new standard is not a sign that the Ministry has gone soft on bacterial contamination of relevant foods.The new standard will come into effect starting Dec. 21, 2011.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

BEIJING, Nov. 17 (Xinhua) -- The Beijing municipal government Thursday launched a news release platform on Sina's weibo.com, China's popular Twitter-like microblogging service.Twenty municipal government agencies will post newly-unveiled policies and regulations, work developments, and information of news conferences on the joint microblog account, said Wang Hui, head of the Beijing municipal government's information office.The government departments will also timely answer hot topics and social concerns, Wang said.Many government departments have their own microblog accounts. The municipal public security bureau, for example, opened its microblog in August last year and now has over 1.8 million followers."I'm happy I can communicate directly with the government. And I hope my viewpoints and suggestions can get attention," said weibo user 1910060523.Many, however, question the move. "Is it really the case that everything can be said here and the government will read the comments and give responses?" said another user.Wang Hui said, "We are not just making a show. We shall be sincere to answer public's concerns over hot topics."